Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06202820 · ClinicalTrials.gov registry record · NA
CV CARE: CardioVascular Care in PC Patients
A NA study of Prostate Cancer and Cardiovascular Diseases, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 180
- Enrollment target
- 2
- Study locations
NCT06202820: Recruiting NA study of Prostate Cancer and Cardiovascular Diseases, sponsored by Dana-Farber Cancer Institute.
NCT06202820 is a NA study of Prostate Cancer and Cardiovascular Diseases that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 180 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (70% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06202820, a NA study of Prostate Cancer and Cardiovascular Diseases, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 180 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with the goal of integrating a standardized method into Dana-Farber Cancer Institute clinics for all such participants. The name of the intervention used in this research study is: CV Care (cardiovascular risk assessment and management program)
Primary Outcome
The percentage of a continued participation rate at week 24 of participants who participate at week 4 in the revised iteration of the program (CV CARE 2).
Conditions Studied
Interventions
- BEHAVIORAL CV Care Program
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2024-01-18 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT06202820 shows while recruiting
NCT06202820 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which CV Care Program is the first listed.
NCT06202820 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06202820 about?
NCT06202820 is a clinical study titled "CV CARE: CardioVascular Care in PC Patients". This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with the goal of integrating a standardized method into Dana-Farber Cancer Institute clinics for all such p...
What is the current status of trial NCT06202820?
This trial is currently recruiting. It is a NA study. The enrollment target is 180 participants. The study started on 2024-01-18. Estimated completion is 2026-12-31.
What conditions does trial NCT06202820 study?
This clinical trial studies the following conditions: Prostate Cancer, Cardiovascular Diseases.
What interventions are being tested in trial NCT06202820?
The interventions under investigation include: CV Care Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT06202820?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06202820 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06202820's enrollment target sits among peer trials
180 240th of 735 higher than 493 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI